SEOUL, June 7 (Reuters) – As Samsung Bioepis raced to be
first to market with a copy of Enbrel, a blockbuster rheumatoid
arthritis drug, countdown clocks reminded workers – heading for
lunch,…
The post Hunting growth, Samsung races to get up to speed on biosimilar drugs appeared first on NASDAQ.